Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...

“Most users tolerate GLP-1 medications like Ozempic without serious oral health issues, but a subset experience notable side ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Dentists claim weight-loss drugs could majorly impact users' saliva glands, helping gum disease to fester in their mouths.

Today, we're diving into a hot topic in the world of health and wellness: semaglutide. You might have heard about this ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...

Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...